Business Context and Reporting Period
This Form 8-K Current Report was filed by CorMedix Inc. on March 21, 2022, covering events occurring on March 16 and March 17, 2022. The filing primarily addresses the appointment of a new Chief Executive Officer (CEO) and the execution of a related employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
- Executive Appointment: Joseph Todisco was appointed as CEO, effective March 16, 2022, with a start date to be mutually agreed upon but no later than May 16, 2022.
- Board Membership: Mr. Todisco was appointed to the Board of Directors on March 18, 2022.
- Interim Leadership: Dr. Matthew T. David will continue as Interim CEO and CFO until Mr. Todisco commences employment, after which Dr. David will serve solely as CFO.
Guidance, Outlook, and Management Commentary
The filing details the terms of the new CEO's employment agreement, which includes:
- Term: Initial three-year term with automatic one-year renewals unless terminated with 90 days' notice.
- Compensation: Annual base salary of $600,000. Target annual bonus of 65% of base salary. For the 2022 fiscal year, a guaranteed minimum bonus of $195,000 (50% of target) is provided.
- Equity Grants:
- Stock option to purchase 500,000 shares, vesting over four years in equal annual installments.
- 207,469 Restricted Stock Units (RSUs) vesting 50% in year one, 30% in year two, and 20% in year three.
- Future annual equity grants commencing in 2023.
- Severance Provisions:
- Termination without Cause/Good Reason: 12 months of base salary, prorated bonus, COBRA premium payments, and accelerated vesting of Initial RSUs and options scheduled to vest by the next anniversary.
- Change in Control (within 24 months): 150% of base salary plus target bonus paid over 18 months, prorated bonus, COBRA payments, and full acceleration of all unvested equity awards.
- Legal Fees: Company will reimburse up to $20,000 for legal fees related to the agreement review.
Investor Verification Checklist
- Verify the exact commencement date of Mr. Todisco's employment (agreed upon by parties, but no later than May 16, 2022).
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Corporate Transaction."
- Confirm the closing price of CorMedix stock on the grant date to determine the exercise price of the 500,000 stock options.
- Monitor the transition of Dr. Matthew T. David from Interim CEO to CFO.